Evidence map›Paper›PMID 36557005›Full record

ArticleMedicina (Kaunas, Lithuania)2022

Comparative RNA-Sequencing Analysis Reveals High Complexity and Heterogeneity of Transcriptomic and Immune Profiles in Hepatocellular Carcinoma Tumors of Viral (HBV, HCV) and Non-Viral Etiology.

Liliana Paslaru, Gabriela Bindea, Anca Nastase, Andrei Sorop, Cristian Zimbru, Vlad Herlea, Doina Hrehoret, Vlad Brasoveanu, Radu Zamfir, Simona Dima and 1 more

Open access · goldAbstract read
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Liliana PaslaruFundeni Clinical Institute, 022328 Bucharest, Romania.
Gabriela BindeaInstitut National de la Santé et de la Recherche Médicale (INSERM), Laboratory of Integrative Cancer Immunology, 75006 Paris, France.ORCID 0000-0001-6013-6645
Anca NastaseFundeni Clinical Institute, 022328 Bucharest, Romania.
Andrei SoropFundeni Clinical Institute, 022328 Bucharest, Romania.ORCID 0000-0002-2617-4629
Cristian ZimbruDepartment of Automation and Applied Informatics, Politehnica University Timisoara, 300223 Timisoara, Romania.ORCID 0000-0002-2652-0931
Vlad HerleaFundeni Clinical Institute, 022328 Bucharest, Romania.ORCID 0000-0002-0125-7815
Doina HrehoretFundeni Clinical Institute, 022328 Bucharest, Romania.
Vlad BrasoveanuFundeni Clinical Institute, 022328 Bucharest, Romania.
Radu ZamfirFundeni Clinical Institute, 022328 Bucharest, Romania.
Simona DimaFundeni Clinical Institute, 022328 Bucharest, Romania.ORCID 0000-0001-5275-8938
Irinel PopescuFundeni Clinical Institute, 022328 Bucharest, Romania.
Institutul Clinic Fundeni · ROInserm · FRPolytechnic University of Timişoara · RO

Funding

Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii 248PED/2017, PN-III-P2-2.1-PED-2016-1826
6 · The paper itself

Abstract

Background and Objectives: Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is the leading cause of cancer-related mortality. It arises and progresses against fibrotic or cirrhotic backgrounds mainly due to infection with hepatitis viruses B (HBV) or C (HCV) or non-viral causes that lead to chronic inflammation and genomic changes. A better understanding of molecular and immune mechanisms in HCC subtypes is needed. Materials and Methods: To identify transcriptional changes in primary HCC tumors with or without hepatitis viral etiology, we analyzed the transcriptomes of 24 patients by next-generation sequencing. Results: We identified common and unique differentially expressed genes for each etiological tumor group and analyzed the expression of SLC, ATP binding cassette, cytochrome 450, cancer testis, and heat shock protein genes. Metascape functional enrichment analysis showed mainly upregulated cell-cycle pathways in HBV and HCV and upregulated cell response to stress in non-viral infection. GeneWalk analysis identified regulator, hub, and moonlighting genes and highlighted CCNB1, ACTN2, BRCA1, IGF1, CDK1, AURKA, AURKB, and TOP2A in the HCV group and HSF1, HSPA1A, HSP90AA1, HSPB1, HSPA5, PTK2, and AURKB in the group without viral infection as hub genes. Immune infiltrate analysis showed that T cell, cytotoxic, and natural killer cell markers were significantly more highly expressed in HCV than in non-viral tumors. Genes associated with monocyte activation had the highest expression levels in HBV, while high expression of genes involved in primary adaptive immune response and complement receptor activity characterized tumors without viral infection. Conclusions: Our comprehensive study underlines the high degree of complexity of immune profiles in the analyzed groups, which adds to the heterogeneous HCC genomic landscape. The biomarkers identified in each HCC group might serve as therapeutic targets.

Indexed as

Carcinoma, HepatocellularHepatitis CLiver NeoplasmsHepatitis B virusHumansMaleRNATranscriptomeRNAbiomarkersHBVHCVhepatocellular carcinomaimmune infiltrateRNA-seq

Identifiers

PMID36557005
PMCPMC9785216
OpenAlexW4311808467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.